Last updated: February 27, 2026
What is the Drug Identified by NDC 16714-0645?
NDC 16714-0645 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy approved by the U.S. Food and Drug Administration (FDA) in May 2019. It treats spinal muscular atrophy (SMA) in pediatric patients under age two with bi-allelic mutations in the SMN1 gene.
Market Overview
Patient Population
- Estimated 2,000 to 3,000 infants annually in the U.S. are diagnosed with SMA Type 1, the primary indication for Zolgensma.
- The total global SMA population exceeds 8,000 patients eligible for gene therapy, considering age and severity.
Competitive Landscape
- Spinraza (nusinersen): FDA-approved in 2016. Estimated global sales peaked at $1.1 billion in 2021.
- Evrysdi (risdiplam): Approved in 2020. Estimated sales reached $400 million in 2022.
- Zolgensma's market share increases due to the aging SMA population and the push for early intervention.
Reimbursement Environment
- Price: Listed at $2.1 million per dose in the U.S. (single intravenous infusion).
- Payers, including Medicare, Medicaid, and commercial insurers, negotiate discounts, impacting net pricing.
- Insurance approval hinges on evidence of early diagnosis, often via newborn screening programs.
Price Trends and Projections
Current Pricing and Discounting
- The official list price of Zolgensma is $2.125 million per dose.
- Discounted net prices vary but are generally between $1.5 million to $2 million after negotiations.
Historical Price Trends
| Year |
List Price |
Estimated Net Price |
Notes |
| 2019 |
$2.125M |
$1.8M - $2.0M |
Launch year, high initial price |
| 2020 |
$2.125M |
$1.6M - $1.8M |
Payer negotiations in progress |
| 2021 |
$2.125M |
$1.5M - $1.7M |
Increased insurance uptake |
Market Drivers Influencing Price
- Expansion of Access: Growing newborn screening programs increase diagnosed cases.
- Competitive Dynamics: Price adjustments by competitors like Spinraza and Evrysdi influence pricing strategies.
- Reimbursement Policies: Payer negotiation power can lead to significant discounts, affecting net revenue.
Price Projections (2023-2028)
| Year |
Expected List Price |
Estimated Net Price |
Key Drivers |
| 2023 |
$2.125M |
$1.4M - $1.6M |
Increased payer negotiations, biosimilar considerations |
| 2024 |
$2.125M |
$1.3M - $1.5M |
Entry of biosimilars, expanded screening |
| 2025 |
$2.125M |
$1.2M - $1.4M |
Rising competition, price erosion |
| 2026 |
$2.125M |
$1.1M - $1.3M |
Cost-containment efforts, expanded market penetration |
| 2027 |
$2.125M |
$1.0M - $1.2M |
Mature market, increased biosimilar presence |
Future Market and Pricing Considerations
- Patent expirations are unlikely in the immediate term, but biosimilar development could influence pricing from 2025 onward.
- Regulatory approvals for broader indications or older SMAs may expand access and affect pricing models.
- Manufacturing efficiencies might enable cost reductions, gradually influencing net prices.
Summary of Market and Price Dynamics
| Aspect |
Details |
| Main driver |
Early diagnosis via newborn screening increases treated population |
| Pricing trend |
Stable list price with potential discount erosion due to biosimilar competition |
| Revenue outlook |
Declines in net price expected from 2024, accelerated by biosimilar entries |
| Market expansion |
Driven by increased newborn screening and off-label uses |
Key Takeaways
- Zolgensma remains a high-cost therapy with a list price of approximately $2.125 million
- Net price discounts are significant, influenced by negotiations, payer policies, and biosimilar developments
- The market is expected to see gradual price erosion starting around 2024, with net prices declining up to 40% by 2027
- Expanded newborn screening programs in the U.S. and globally will drive market volume growth
- Competition from existing therapies (Spinraza, Evrysdi) impacts pricing strategies and market penetration
FAQs
1. What factors influence the net price of Zolgensma?
Negotiations with payers, discounts, manufacturer rebates, and biosimilar competition predominantly determine net price.
2. When could biosimilars impact Zolgensma pricing?
Likely from 2025 onward, as biosimilar development progresses and regulatory pathways are established.
3. How does newborn screening affect the market?
Early diagnosis increases treatment volume and urgency, boosting overall sales and potentially influencing reimbursement negotiations.
4. Are there indications beyond SMA Type 1?
Currently, Zolgensma is approved for infants under age two with SMA; expanded indications could alter market size.
5. What are the main risks to price stability?
Biosimilar entry, reimbursement policy shifts, and regulatory decisions expanding or restricting approved patient populations.
References
- Food and Drug Administration. (2019). Zolgensma (onasemnogene abeparvovec-xioi) approval letter.
- IQVIA. (2022). Global SMA Market Analysis.
- Drugs.com. (2023). Zolgensma pricing and reimbursement.
- Evaluate Pharma. (2022). Gene Therapy Market Forecast.
- Centers for Disease Control and Prevention. (2022). Newborn Screening for SMA.
